AccuStem Sciences, Inc. (ACUT)

OTCMKTS · Delayed Price · Currency is USD
0.431
-0.009 (-2.05%)
At close: Feb 26, 2026
75.92%
Market Cap 6.93M
Revenue (ttm) n/a
Net Income (ttm) -1.61M
Shares Out 16.07M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,283
Average Volume 2,552
Open 0.440
Previous Close 0.440
Day's Range 0.431 - 0.440
52-Week Range 0.253 - 2.330
Beta 2.38
RSI 34.04
Earnings Date Feb 27, 2026

About AccuStem Sciences

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. It offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. The company also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company has a partnership with EmeritusDX for the development of non-inva... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol ACUT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.